CFDA Number
93.279
Unique assistance listing ID
CFDA 93.279 — federal assistance program administered by National Institutes of Health, sourced from the SAM.gov Assistance Listings catalog.
Administered by National Institutes of Health (NIH)
Program overview. CFDA 93.279 — Drug Abuse Research Programs — is a federal assistance listing in the Health category, administered by National Institutes of Health (NIH). The typical award range cataloged on SAM.gov is $100,000 to $3.0 million. The program is currently active in the SAM.gov Assistance Listings database. Eligible applicants include Educational Institution.
Funding opportunities. PlainGrants has indexed 20 Grants.gov opportunity announcements tied to CFDA 93.279. Of those, 20 are currently open for applications and 0 have closed. The next closing date is September 7, 2026. The largest award ceiling seen across these announcements is $3.0 million. Agencies have projected roughly $750,000 in total estimated funding across the indexed announcements for this CFDA number. Individual Notice of Funding Opportunity documents on Grants.gov carry the exact deadlines, required forms, and submission instructions.
Next steps. Before applying for CFDA 93.279, confirm your organization has an active SAM.gov registration and a Unique Entity ID (UEI) — these are mandatory for every federal funding instrument. Read the current Notice of Funding Opportunity end-to-end, paying close attention to the cost-share or matching requirement, the evaluation criteria, and the narrative page limits. Health-category grants routinely require Institutional Review Board (IRB) approval for any research involving human subjects and may require Single Project Assurance registration. For structural help, the guides linked below cover SAM.gov setup, NOFO interpretation, and common rejection reasons.
CFDA Number
93.279
Unique assistance listing ID
Category
Health
Federal grant subject area
Open Opportunities
20
Currently open for applications
$100,000 to $3.0 million
Typical Award Range
$100,000 to $3.0 million
Application Deadline
Annual
Category
Health
Research on causes, consequences, treatment, and prevention of drug abuse and addiction.
Ready to Apply?
Visit the official program website for current application requirements and deadlines.
National Institutes of Health
Biomedical and behavioral research grants for universities, institutions, and investigators.
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)
NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)
D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional)
Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)
Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)
Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)
Showing 10 of 20 opportunities.
Adoption Assistance
Advanced Education Nursing Traineeships
Advanced Nursing Education Workforce
Alcohol Research Center Grants
Alcohol Research Programs
Disclaimer: This information is sourced from SAM.gov Assistance Listings (CFDA) and is for informational purposes only. Program requirements, deadlines, and availability change frequently. Always verify current requirements directly with the awarding agency before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology — how this data is sourced, computed, and verified.
| Publisher | Kiznis Studio |
| Sources | Public official public datasets |